Xilio Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Xilio Therapeutics, Inc. (XLO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $14.18 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.40, a 506.38% increase year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.88, a 75.65% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.72, a 4.89% increase year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $7.36, a 46.32% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $50.00, a 865.25% increase from fiscal 2024.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $5.18, a 28.65% decline from fiscal 2023.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $7.26, a 30.13% decline from fiscal 2022.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $10.39, a 67.04% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.18 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $11.40 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $50.00 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $3.70 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $4.25 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.88 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $5.18 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $5.36 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $5.07 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $7.72 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $7.26 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $6.77 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $7.35 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $7.36 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $10.39 10-K · filed 2023-03-02 | |||
| 2022-09-30 | $10.23 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $9.04 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $13.71 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $6.22 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $6.17 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |